Clik here to view.
Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal
A new, still-in-stealth biotech is paying eight figures to acquire the rights to an experimental I&I drug out of China. Vignette Bio — a company backed by Foresite Capital and Samsara BioCapital,...
View ArticleVaxcyte aims to raise $1B after sharing pneumococcal vaccine data; More...
Plus, news about Anthos, Ascendis, Royalty Pharma, Semnur, Sonoma, Atara, Feldan, Indivior, Aelis Farma and Acepodia: Vaxcyte launches $1B offering: The raise comes fresh off the company’s pneumococcal...
View ArticleNovartis expands radioligand therapy manufacturing in California and...
Novartis is putting $200 million into its radioligand therapy manufacturing capabilities with a new site in California and the expansion of an existing site in Indianapolis. The Indianapolis site will...
View ArticleCourt orders J&J to pay $1B following buyout of surgical robotics company
Johnson & Johnson paid $3.4 billion upfront for the surgical robotics company Auris Health in 2019, with the potential for $2.35 billion more in commercial and regulatory milestones. But a Delaware...
View ArticleModerna’s mpox vaccine outperforms approved version in preclinical study
Preclinical data suggest that Moderna’s mpox vaccine could be superior to other alternatives currently approved, according to new research published Wednesday. Scientists reported in the journal Cell...
View ArticleHigher dose of Spinraza helped spinal muscular atrophy patients, Biogen says
Biogen on Wednesday said that an experimental, higher dose of its spinal muscular atrophy drug Spinraza met the primary endpoint of a clinical trial comparing it with a historical control group. It now...
View ArticleClik here to view.
BioMarin restructures following staff shakeup, slow Roctavian sales
BioMarin laid out a new corporate strategy on Wednesday, following months of reorganization and multiple staff reductions. The new structure relies on three key business units: skeletal conditions,...
View ArticleClik here to view.
IN8bio pauses glioblastoma program, halves workforce as it prioritizes...
IN8bio is putting its brain tumor development program on the back burner and axing almost half of its employees in an effort to cut costs and divert resources to an early-phase blood cancer asset. The...
View ArticleClik here to view.
Lilly unveils more positive late-stage data for its once-weekly insulin
On Thursday, Eli Lilly dropped more data for its once-weekly insulin candidate in adults with type 2 diabetes. In two Phase 3 trials, dubbed QWINT-1 and QWINT-3, Lilly’s efsitora alfa showed...
View ArticleExclusive: ZipBio launches using generative AI to make compact proteins
As several well-funded companies race to make generative AI models that can design new protein therapies from scratch, one small startup has found a new use for existing AI systems: compressing large...
View ArticleAstellas to close facility in California; Takeda can make more of its ADHD drug
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Astellas Gene Therapies is shuttering its facility in San Francisco...
View ArticleClik here to view.
MDLive veterans nab $7.5M Series A for virtual specialty care startup
(This story is from our Health Tech newsletter. If you’d like to sign up, just click here.) Circadian Health, a startup that provides virtual specialist care for chronic diseases, has raised $7.5...
View ArticleNovartis pays $15M upfront to license Voyager program; Boehringer advances...
Plus, news about Jnana Therapeutics, Vaxcyte, C-Further, Genprex, PharmaEssentia, FORUS Therapeutics, Pharma Two B and Hepion: Novartis licenses Voyager program: Voyager will get $15 million upfront...
View ArticleThe Endpoints 11 event is coming: Meet biotech’s hottest new startups
For the last few months, our team at Endpoints News has been looking over dozens of new startups to find the ones we think are pursuing the most interesting scientific ideas, backed with the right...
View ArticleClik here to view.
Lykos CEO Amy Emerson resigns
Amy Emerson resigned as CEO of Lykos Therapeutics, a biotech that spent a decade advancing MDMA-assisted therapy as a treatment for post-traumatic stress disorder and faced a debilitating FDA rejection...
View ArticleCigna offers discounted Stelara biosimilar, building on Humira move
Evernorth, the health services arm of insurance behemoth Cigna, is planning to make a Stelara biosimilar available for $0 out-of-pocket for select patients. The move, announced Thursday, applies to...
View ArticleEuropean court reinstates Advanz's liver disease drug after EC revocation
Advanz Pharma scored a win for its liver disease treatment Ocaliva after the General Court of the European Union temporarily suspended the European Commission’s decision to revoke the conditional...
View ArticleJ&J increases talc settlement by $1.1B after negotiating with plaintiffs,...
Johnson & Johnson agreed to increase its talc settlement plan by $1.1 billion after negotiating with plaintiffs’ lawyers, according to one of the attorneys. The bankruptcy plan would settle 99% of...
View ArticleCBER chief forecasts better global regulatory convergence around cell and...
Peter Marks, who’s responsible for the FDA’s oversight of cell and gene therapies, expects regulators around the world will be better at collaborating on gene therapy approvals within the next five...
View ArticleFDA raises antimicrobial resistance concerns ahead of adcomm for Iterum's UTI...
The FDA has raised concerns about potential “inappropriate use” of Iterum’s oral candidate for uncomplicated urinary tract infections (uUTIs) ahead of a Monday advisory committee meeting. If approved,...
View Article